Vanda Pharmaceuticals (NASDAQ:VNDA) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.09 by 33.33 percent. This is a 57.14 percent decrease over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $65.32 million which missed the analyst consensus estimate of $71.00 million by 8.00 percent. This is a 6.82 percent decrease over sales of $70.09 million the same period last year.
Draganfly Wins Canadian Provincial Wildfire Services Contract, Terms Undisclosed
Draganfly Inc. (NASDAQ:DPRO) (CSE:DPRO) (FSE: 3U8A) ("Draganfly" or the "Company"), an award-winning, industry-leading drone solution, and systems developer is pleased to announce it will be providing
